Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel and first-in-class DNA-decoy therapies targeting proteins implicated in tumors and inflammatory disease processes.
Our therapeutic strategy focuses on fighting intracellular pathways dysregulations, in fields that pose greater therapeutic challenges. Our approach is based upon unique mechanisms of action on intracellular DNA-binding proteins. We focus on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in human cancer and inflammatory indications with high unmet needs.
We seek to transform breakthrough scientific opportunities into treatments through translational and clinical expertise, developing products to the stage where they are compelling opportunities for partners. Therefore, we are focused on advancing products from the preclinical stage to optimal inflection points (usually phase 2 clinical proof-of-concept studies). Once proof of concept is established, we seek to monetize the assets through various types of deals, thereby generating revenue and value.
Our inherent value rests on the significant potential of our product pipeline and the expertise of our highly professional team.